{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": "[-28, -2]",
        "relativeTo": "First Dose",
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": "[3, 14]",
        "relativeTo": "Previous Visit",
        "windowLower": 3,
        "windowUpper": 14
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Last Dose",
        "windowLower": 0
      },
      {
        "id": "timing_5",
        "name": "Additional Follow-up for TE ADA",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_6",
        "name": "Study Drug Administration after Hypoglycemia Induction",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5,
        "windowLower": 0,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Admission Rescheduling Condition",
        "instanceType": "Condition",
        "description": "Admission can be rescheduled if plasma glucose is outside the specified range on Day 1.",
        "text": "PG level is not 90 to 250 mg/dL on Day 1."
      },
      {
        "id": "cond_2",
        "name": "Stop Insulin Infusion Condition",
        "instanceType": "Condition",
        "description": "Criteria to stop the insulin infusion during the hypoglycemia induction procedure.",
        "text": "Bedside PG is <60 mg/dL."
      },
      {
        "id": "cond_3",
        "name": "Interim Safety Review",
        "instanceType": "Condition",
        "description": "A safety review is required after the first 6 patients complete Period 2 before dosing remaining patients.",
        "text": "Safety data will be reviewed after the first 6 patients are administered LY900018 in Period 2, and the remaining patients will be dosed after confirmation of the safety."
      },
      {
        "id": "cond_4",
        "name": "Study Stopping Rule",
        "instanceType": "Condition",
        "description": "The entire study may be stopped based on the interim safety review.",
        "text": "Following the review of the safety data from the first 6 patients to complete Period 2 Day 1, the study will be stopped if deemed necessary for patient safety in the opinion of the Investigator and sponsor."
      },
      {
        "id": "cond_5",
        "name": "Patient Replacement Criteria",
        "instanceType": "Condition",
        "description": "Criteria for replacing a patient who discontinues from the study.",
        "text": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced."
      },
      {
        "id": "cond_6",
        "name": "Patient Replacement Limit",
        "instanceType": "Condition",
        "description": "Condition limiting the total number of enrolled patients when replacing subjects.",
        "text": "Replacement should not occur beyond 75 patients enrolled, if it is expected to have at least 66 patients complete the study."
      },
      {
        "id": "cond_7",
        "name": "Inadvertently Enrolled Patient Review",
        "instanceType": "Condition",
        "description": "Procedure for determining if an inadvertently enrolled patient can continue in the study.",
        "text": "If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was inadvertently enrolled, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue in the study."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screen to Treatment Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_treatment",
        "text": "Subject must meet all eligibility criteria and be randomized prior to study drug administration on Period 1 Day 1."
      },
      {
        "id": "trans_2",
        "name": "Transition to Additional Follow-up",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_followup",
        "toElementId": "epoch_additional_followup",
        "text": "Patients with treatment-emergent antidrug antibodies (TE ADA) at follow-up/ED will undergo additional follow-up."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of all protocol-required visits, including the final follow-up visit."
      },
      {
        "id": "exit_2",
        "name": "Completion of Additional Follow-up",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Criteria for completing the additional follow-up period for TE ADA positive patients."
      },
      {
        "id": "exit_3",
        "name": "Discontinuation for Other Study Enrollment",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient is discontinued for enrolling in another incompatible clinical study."
      },
      {
        "id": "exit_4",
        "name": "Discontinuation for Medical, Safety, or Regulatory Reasons",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient is discontinued for various reasons consistent with regulations and good clinical practice."
      },
      {
        "id": "exit_5",
        "name": "Discontinuation by Investigator Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The investigator decides to discontinue the patient from the study for any reason."
      },
      {
        "id": "exit_6",
        "name": "Discontinuation by Patient Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The patient or their legal representative requests to be withdrawn from the study."
      },
      {
        "id": "exit_7",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient is considered lost to follow-up if they repeatedly fail to return for scheduled visits and cannot be contacted."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Decision to Continue Dosing",
        "timepointId": "After first 6 patients complete Period 2",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to continue dosing remaining patients or stop the study based on interim safety review.",
        "conditionIds": [
          "cond_3",
          "cond_4"
        ]
      },
      {
        "id": "dec_2",
        "name": "Decision on Inadvertently Enrolled Patient",
        "timepointId": "Upon discovery of inadvertent enrollment",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to determine if an inadvertently enrolled patient may continue in the study.",
        "conditionIds": [
          "cond_7"
        ]
      }
    ],
    "summary": {
      "timingCount": 6,
      "conditionCount": 7,
      "transitionRuleCount": 2,
      "exitCount": 7
    }
  }
}